Skip to main content
Premium Trial:

Request an Annual Quote

Maxygen Raises $110 M In Initial Public Offering

Premium

R

EDWOOD CITY, Calif.--Maxygen late last month announced its initial public offering of 6.9 million shares of common stock at $16 per share. Shares opened at $36 and climbed on volume of 7.7 million to close at $42. Net proceeds to Maxygen totaled $102 million. The company said its proprietary MolecularBreeding directed molecular evolution technologies bring together advances in molecular biology and classical breeding while capitalizing on information generated by genomics research. One week after its IPO, Maxygen shares were being traded at over $68.

Filed under

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.